Last week, Moderna announced that it has received approval from the Food and Drug Administration (FDA) for the development of an mRNA vaccine for respiratory syncytial virus (RSV).
A study from the University of Texas Medical Branch found that the risk of suicide increased twelve times following gender-transition surgery compared to those who did not undergo transgender surgery.